Replies to post #75096 on Biotech Values

[DewDiligence]

MNTA – Thanks, drbio, for the Leerink Swann report.

Joseph Schwartz (analyst): Teva likely submitted the CP seeking to stall M-356 [generic Copaxone] in its regulatory pathway…

“Likely” strikes me as unduly timid on the analyst’s part; is there another reason why Teva would have submitted the Copaxone CP? (Rhetorical question—no need to reply.)

[genisi]

Now that the FDA has rejected Teva's CP, we anticipate it will file another CP

I don't know why this analyst thinks that the FDA rejected the CP. It is my understanding that the FDA didn't reject the CP, rather it delayed its decision to a more appropriate time. I find the FDA response to be a non event to both sides. On one thing I do agree with the writer -

Teva likely submitted the CP seeking to stall M-356 in its regulatory pathway.